Recent Transactions

20-Apr-17
$4.3 billion
Canada flag
Target: 

Brookfield Canada Office Properties

United States flag
Acquiror: 
Brookfield Property Partners L.P.

Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.

27-Apr-21
$4.2 billion
Australia flag
Target: 

AMP Capital Diversified Property Fund

Australia flag
Acquiror: 
Dexus and Dexus Wholesale Property Fund

Advised ASX-listed real estate investment trust Dexus and its unlisted diversified property fund, Dexus Wholesale Property Fund, on Dexus Wholesale Property Fund’s merger with AMP Capital Diversified Property Fund

15-Aug-18
$3.9 billion
Canada flag
Target: 

Common shares and common share purchase warrants in Canopy Growth

United States flag
Acquiror: 
Constellation Brands

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

26-Oct-11
$2.2 billion
U.S.A., Japan flags
Target: 

PGM Holdings K.K. (majority owned by Lone Star Funds)

Japan flag
Acquiror: 
Heiwa Corporation

Advised Heiwa Corporation, a leading provider of pachinko amusement machines, on the tender offer to acquire 80.5% of PGM Holdings K.K., one of the largest golf club owners and operators in Japan, including 64.2% Lone Star Funds’ holding

14-Jul-21
$2.2 billion
Australia flag
Target: 

Australian Unity Funds Management

Acquiror: 
NorthWest Healthcare Properties REIT, GIC

Advised Australian Unity Funds Management on its successful defence of Australian Unity Healthcare Property Trust, in response to four unsolicited offers from a consortium comprised of NorthWest Healthcare Properties REIT and Singaporean sovereign wealth fund, GIC

05-Aug-21
$2 billion
Canada flag
Target: 

Score Media and Gaming, Inc.

United States flag
Acquiror: 
Penn National Gaming, Inc.

Advising the Board of Directors of Score Media and Gaming (“theScore”), a leading digital media and sports betting and technology company, regarding the acquisition of theScore by Penn National Gaming

20-Nov-20
$1.6 billion
Japan flag
Target: 

Kenedix

Japan flag
Acquiror: 
Sumitomo Mitsui Finance and Leasing

Advising Kenedix, one of the largest Japanese independent real estate asset managers, on its acquisition by Sumitomo Mitsui Finance and Leasing, one of the largest Japanese leasing companies

08-Aug-16
$1.5 billion
Canada flag
Target: 

Whistler Blackcomb Holdings Inc.

United States flag
Acquiror: 
Vail Resorts, Inc.

Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.

02-May-19
$1.0 billion
Australia flag
Target: 

80 Collins Precinct

Australia flag
Acquiror: 
Dexus

Advised Dexus in relation to its acquisition of the 80 Collins precinct from QIC Global Real Estate

26-Apr-19
$1.0 billion
United States flag
Target: 

T5 Data Centers Strategic Partnership

Canada flag
Acquiror: 
QuadReal

Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

30-Jun-11
$609 million
Japan flag
Target: 

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

United States flag
Acquiror: 
Royalty Pharma

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

10-Mar-10
$576 million
United Kingdom flag
Target: 

Camelot Group plc

Canada flag
Acquiror: 
Ontario Teachers’ Pensions Plan

Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan

26-Mar-12
$513 million
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

United States flag
Acquiror: 
Bausch + Lomb, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

07-Jul-23
Pending
$439 million
Australia flag
Target: 

Australian Unity Diversified Property Fund

Australia flag
Acquiror: 
Cromwell Direct Property Fund

Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

23-Sep-10
$394 million
Australia flag
Target: 

Aevum Ltd.

Australia flag
Acquiror: 
Stockland Corp. Ltd

Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group

26-May-11
$192 million
Australia flag
Target: 

Centrebet International Limited

United Kingdom flag
Acquiror: 
Sportingbet plc

Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

07-Dec-21
$153 million
Japan flag
Target: 

Japan Medical Dynamic Marketing

Japan flag
Acquiror: 
Mitsui Chemicals

Advising Mitsui Chemicals,  one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

10-Sep-18
$100 million
Australia flag
Target: 

Montserrat Day Hospital Group

Australia flag
Acquiror: 
Primary Health Care

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Pages

show all